Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis

Area of Science:

• Oncology
• Medical Oncology
• Translational Research

Background:

• Brain metastasis (BM) is a significant challenge in metastatic breast cancer (MBC), particularly in human epidermal growth factor receptor 2-positive (HER2+) cases, affecting up to 50% of patients.
• Historically, HER2+ BM patients were underrepresented in clinical trials, but recent research highlights novel HER2-targeted agents for both stable and progressing BM, including leptomeningeal carcinomatosis (LMC).

Purpose of the Study:

• To review current data on the treatment of HER2-positive brain metastasis (BM) and leptomeningeal carcinomatosis (LMC).
• To summarize the efficacy and clinical benefit of emerging HER2-targeted therapies in the central nervous system.

Main Methods:

• Literature review of recent clinical trials and studies.
• Analysis of data on HER2-targeted agents in HER2-positive breast cancer patients with brain metastases.
• Synthesis of evidence regarding intracranial activity and clinical outcomes.

Main Results:

• Accumulating evidence demonstrates the intracranial activity and clinical benefit of novel anti-HER2 therapies in HER2+ BM and LMC.
• These therapies are increasingly being investigated and utilized in clinical settings for HER2+ metastatic breast cancer patients with central nervous system involvement.

Conclusions:

• The treatment landscape for HER2-positive metastatic breast cancer with brain involvement is evolving.
• While local therapies remain important, systemic anti-HER2 targeted therapies are showing promise and may lead to a paradigm shift in managing HER2+ BM and LMC.